Enlarge / We've all been there. (credit: Getty | Ute Grabowsky) A fast-acting drug that shortens influenza infections with a single dose has earned a priority review from the US Food and Drug Administration and—if approved—has the chance of hitting the market in 2019 amid the upcoming flu season. That’s all according to Genentech, the Roche-based company that is developing the drug, baloxavir marboxil, for the US market. Baloxavir marboxil is garnering attention in part because of its timing.